|  |  |
| --- | --- |
| GENERAL INFORMATION | |
| 1. **NAME OF THE CENTER AND LOCATION** | |
|  | ***Faculty of Biology, Sofia University “St. Kliment Ohridski”***  *8 Dragan Tsankov Blvd, 1164 Sofia*  [*URL:https://www.uni-sofia.bg/index.php/bul/universitet\_t/fakulteti/biologicheski\_fakultet2*](URL:https://www.uni-sofia.bg/index.php/bul/universitet_t/fakulteti/biologicheski_fakultet2)  *E-mail:* [*bf-decanat@biofac.uni-sofia.bg*](mailto:bf-decanat@biofac.uni-sofia.bg) *- Биологически факултет, Деканат* |
|  |
| 1. **TYPE OF THE RESEARCH INFRASTRUCTURE AND/OR SCIENTIFIC EXPERTISE** | |
| Identify the type of the RI, equipment/facilities/ specific research, and in particular linked to COVID-19: | Available facilities and equipment positioned in the Faculty of Biology of the University include routine facilities for eukaryotic and prokaryotic cell culture and characterisation, animal histology and embryology units, laboratories for molecular biology and molecular genetics with ELISA methodology, RNA/DNA isolation, purification and quantification facilities, analytical tools, core facility for immune fluorescent microscopy incl. high resolution imaging platform for wide field microscopy with 3D deconvolution Delta Vision Ultra™, GE Healthcare, routine phase contrast, upright and inverted fluorescent microscopes cryopreservation facilities, routine and specific equipment for microbiology, virology and biotechnology. The Faculty possesses its own biobanks for cell-lines from eukaryotes and prokaryotes, Genetics unit with collection of model animals (Drosophila m.), animal facilities for laboratory species (at reconstruction under Co C of OP NOIR) and GMO accredited laboratories.  Expertise at the Faculty of Biology can contribute to the development of cell-based 2D and 3D culture assays for biological testing of drug substances and materials for pharmaceutical and biomedical applications by means of fluorescent and light microscopy, spectrophotometry and computer assisted analysis for qualitative and quantitative cytotoxicity testing; cellular stress response; cell proliferation and apoptosis; routine molecular biology, protein & genetic testing by Western & PCR techniques.  Following laboratories can provide expertise and execution of specific tasks:  - Laboratory for biophysics and model membranes  - Laboratory for cell electroporation with a cultivation block  - Laboratory for synthetic biology and RNA: RNA-based antibiotics (ribosomes)  - Biotechnological production of biologically active substances  - Laboratories for microbiological control and virology  - Laboratory for experimental animal and cell biology – development of models based on small animals and cell lines for toxicology testing and drug development    KEY WORDS:  Expertise in infection diseases - microbiological control, virology, in vitro cytotoxicity testing |
| 1. **TYPE OF THE RESEARCH** | |
| Provide information on the research carried on or planned in regard with COVID-19 and other viruses | Expertise at the Faculty of Biology can contribute to the development of cell-based 2D and 3D culture assays for biological testing of drug substances and materials for pharmaceutical and biomedical applications: biological compatibility of different nanoparticles, designed for delivery of biological macromolecules such as DNA, RNA and proteins with potential use in biomedical studies; in vitro studying of bacteria-host cell interactions; biological activity of plant secondary metabolites with potential biomedical applications  Related expertise and projects:  1. Testing of face masks and filters for their protection against infectious agents, including SARSCo-2.  2. Screening of substances synthetic and natural substances for anti-coronavirus activities in vitro  3. Biological properties of different nanoparticles, designed for delivery of biological macromolecules such as DNA, RNA and proteins with potential use in biomedical studies;  4. In vitro research on bacteria-host cell interactions, cell toxicity tests using lung adenocarcinoma cell line A549 |
| 5. Design of formulations for further RNAi-based therapy of CoVID-19. Objective is to design RNAi precursors and nanoparticles suitable for development of inhalation therapy for CoVID-19. |
| 1. **WEBSITE** | |
| Provide the internet address: | *URL:* <https://www.uni-sofia.bg/index.php/bul/universitet_t/fakulteti/biologicheski_fakultet2> |
| 1. **BACKGROUND, PUBLICATIONS AND OPEN DATA REPOSITORY** | |
| leading research team AND Scientific publications of the research group on the topics of related to coronaviruses research results**;**  **link to open data repository** | **Virology laboratory**:  Prof. Stoyan Shishkov, Head, PhD - [sshishkov@biofac.uni-sofia.bg](mailto:sshishkov@biofac.uni-sofia.bg)  Assist. Prof. Daniel Todorov, PhD - [dani\_todorov@abv.bg](mailto:dani_todorov@abv.bg)  **In-vitro cytotoxicity laboratory:**  Assoc Prof. Tanya Topouzova Hristova, PhD - [topouzova@biofac.uni-sofia.bg](mailto:topouzova@biofac.uni-sofia.bg)  Assist/ Prof. Georgi Nikolaev, PhD - [gn\_georgiev@uni-sofia.bg](mailto:gn_georgiev@uni-sofia.bg)   * Tsvetkov, V. et al., Effect of plasma activated medium and water on replication and extracellular virions of HSV-1, 2020, Plasma medicine, in press, 10.1615/PlasmaMed.2020033626. * Chayrov R., E. Stylos, M. Chatziathanasiadou, K. Chuchkov, A. Tencheva, A. Kostagianni, T. Milkova, A. Angelova, A. Galabov, S. Shishkov, D. Todorov, A. Tzakos, I. Stankova. 2018. Tailoring acyclovir prodrugs with enhanced antiviral activity: rational design, synthesis, human plasma stability and in vitro evaluation. Amino Acids. DOI: 10.1007/s00726-018-2590-y. * Shishkova K., I. Tsekov, R. Popov, S. Shishkov, Z. Kalvatchev. 2014. PCR Systems for Detection of Novel Elusive Human Pathogens Torque Teno Viruses (TTVs) in Bulgaria. Compt. Rend. l’Acad. Bulg. Sci., 67 (8):1175-1186. * Zahmanov, G., K. Alipieva, P. Denev, D. Todorov, A. Hinkov, S. Shishkov, S. Simova, M.I. Georgiev. 2015. Flavonoid glycosides profiling in dwarf elder fruits (Sambucus ebulus L.) and evaluation of their antioxidant and anti-herpes simplex activities. Industrial Crops and Products, 63: 58–64. * E. Haladjova, S. Halacheva, D. Momekova, V. Moskova-Doumanova, T. Topouzova-Hristova, K. Mladenova, J. Doumanov, M. Petrova, S. Rangelov. Polyplex Particles Based on Comb-Like Polyethylenimine/Poly(2-ethyl-2-oxazoline) Copolymers: Relating Biological Performance with Morphology and Structure. Macromol. Biosci. 2018, 1700349. https://doi.org/10.1002/mabi.201700349 * Radostina Kalinova, Jordan A. Doumanov, Kirilka Mladenova, Dushica Janevska, Milena Georgieva, George Miloshev, Tanya Topouzova-Hristova, and Ivaylo Dimitrov. Rational Design of Polypeptide-Based Block Copolymer for Nonviral Gene Delivery, Chemistry Select 2017, 2, 12006 – 12013; DOI: 10.1002/slct.201702403 * Haladjova, E., Kyulavska, M., Doumanov, J., Topouzova-Hristova, T., Petrov, P. Polymeric vehicles for transport and delivery of DNA via cationic micelle template method. Colloid Polym Sci (2017). https://doi.org/10.1007/s00396-017-4193-7 * Madalina G. Albu, Todorka G. Vladkova , Iliana A. Ivanova, Ahmed S. A. Shalaby, Veselina S. Moskova-Doumanova, Anna D. Staneva, Yanko B. Dimitriev, Anelya S. Kostadinova, Tanya I. Topouzova-Hristova. 2016. Preparation and Biological Activity of New Collagen Composites, Part I: Collagen/Zinc Titanate Nanocomposites. Applied Biochemistry and Biotechnology, 180(1):177-93; DOI 10.1007/s12010-016-2092-x * Emi Radoslavova Haladjova, Silvia S Halacheva, Vilma Posheva, Ekaterina Peycheva, Veselina Moskova-Doumanova, Tanya Topouzova-Hristova, Jordan Doumanov, Stanislav Miletiev Rangelov. Comb-like Polyethyleneimine-based Polyplexes: Balancing Toxicity, Cell Internalization, and Transfection Efficiency via Polymer Chain Topology. 2015. Langmuir 31 (36), pp 10017–10025 DOI:10.1021/acs.langmuir.5b02408 * Vukova TI, Dimitrov SD, Gagov HS, Dimitrova DZ. (2016) In focus: Fe3O4 nanoparticles and human mesenteric artery interaction in vitro. Nanomedicine (Lond). 11(8): 921-32. IF 4.93 * Mircheva, K., Petrova, S.D., Ivanova, T., Panaiotov, I., Balashev, K.T. Action of Vipoxin and its separated components on monomolecular film of dilauroylphosphatidylcholine at the air/water interface. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 562, 2019, 196-202. * T.D. Andreeva, S.D. Petrova, K. Mladenova, V. Moskova-Doumanova, T. Topouzova-Hristova, N. Mladenov, K. Balashev, Z. Lalchev, J. Doumanov Effects of Ca2+, Glu and GABA on hBest1 and composite hBest1/POPC surface films. Colloids and Surfaces B: Biointerfaces, 161, 2018, 192-199. * A. Chanachev, S. Simeonova, P. Georgiev, Tz. Ivanova, S. Petrova, K. Balashev. Characterization by atomic force microscopy of gold nanoparticles functionalized with azocasein for protease colorimetric enzyme assay. Bulgarian chemical communication 50, 2018, 223-227. * Penchovsky, R., Computational design of allosteric ribozymes as Molecular Biosensors, Biotechnology Advances, DOI: 10.1016/j.biotechadv.2014.05.005 (2014). * Penchovsky, R., Chapter 16: Nucleic Acids-based Nanotechnology; Engineering Principals and Applications, Handbook of Research on Nanoscience, Nanotechnology, and Advanced Materials; Engineering Sciences Reference: An Imprint of IGI Global DOI: 10.4018/978-1-4666-5824-0.ch016, 414-430 (2014). * Penchovsky, R., Programmable and automated bead-based microfluidics for versatile DNA microarrays under isothermal conditions. Lab on a chip, 13, 2370-2380 (2013). * Penchovsky, R., Computational design and biosensor applications of small molecule-sensing allosteric ribozymes. Biomacromolecules, 14, 1240-1249 (2013). * Penchovsky, R. & Kostova, G. Computational selection and experimental validation of allosteric ribozymes that sense a specific sequence of human telomerase reverse transcriptase mRNAs as universal anticancer therapy agents. Nucleic Acid Therapeutics, 23, 408-431 (2013). * Penchovsky R. & Stoilova C.C., Riboswitch-based antibacterial drug discovery using high-throughput screening methods. Expert Opinion on Drug Discovery, 8, 65-82. (2013). * Penchovsky R., Engineering integrated digital circuits with allosteric ribozymes for scaling up molecular computation and diagnostics. ACS Synthetic Biology, 1, 471-482 (2012). * Penchovsky R., Chapter 5: Engineering Gene Control Circuits with Allosteric Ribozymes in Human Cells as a Medicine of the Future, in the book "Quality Assurance in Healthcare Service Delivery, Nursing and Personalized Medicine: Technologies and Processes", Publisher IGI Global, DOI: 10.4018/978-1-120-7, 71-96 (2012). * Breaker R.R. & Penchovsky, R., USA patent: US20110288826, Computational design of ribozymes (2011). * Blount, K., Puskarz, I., Penchovsky, R. & Breaker, R.R. Development and application of a high-throughput assay for glmS Riboswitch Activators. RNA Biology, 3, 77-81 (2006). * Penchovsky, R. & Breaker, R.R. Computational design and experimental validation of oligonucleotide-sensing allosteric ribozymes. Nature Biotechnology, 31, 1424-143 (2005). |
| 1. **COORDINATOR** | |
|  | *Full name of the coordinator organization; Faculty of Biology, Sofia University* |
| *Contact person: Prof. Stoyqn Shishkov – Dean of Faculty of Biology,* |
| *e-mail* [*sshishkov@biofac.uni-sofia.bg*](mailto:sshishkov@biofac.uni-sofia.bg)  *Contact: Prof. Rossitza Konakchieva, Coordinator INFRAACT of NRRI 2017-2023*  *E-mail:* [*r.konakchieva@biofac.uni-sofia.bg*](mailto:r.konakchieva@biofac.uni-sofia.bg) |
| 1. **POSIBLE PARTNERS** | |
| Indicate the partner organizations | *Institute of Organic Chemistry with Centre of Phytochemistry (IOCCP),* |
| *Bulgarian Academy of Sciense* |
| *Prof. Pavlina Dolashka, PhD* |
| *E-mail: pda54@abv.bg* |
|  |
|  | *ReproBioMed Medical Center,*  *Sofia 1618, Ovcha kupel,*  *28, Boicho Ognianov street*  *URL:* [*www.reprobiomed.eu*](http://www.reprobiomed.eu)  *TTO in molecular genetics, virology testing, RNA extraction, Real-time PCR, NGS - Associate partner in the Research Infrastructure Cell Technologies in Biomedicine (INFRAACT)of the National Roadmap for RI 2017-2023*  *URL:* <http://www.alliancecelltechnologies.eu/en/organizations> |
|  | *Joint Genomic Center Ltd*  *8 Dragan Tsankov Blvd, 1164 Sofia*  *URL*: <http://www.alliancecelltechnologies.eu/en/organizations/joint-genomic-center>  *Associate partner in the Research Infrastructure Cell Technologies in Biomedicine (INFRAACT)of the National Roadmap for RI 2017-2023*  Contact: Academician Atanas Atanassov: [atanas\_atanassov@jgc-bg.org](mailto:atanas_atanassov@jgc-bg.org) Assoc. Prof. Ivelin Pantchev: [ipanchev@abv.bg](mailto:ipanchev@abv.bg) |
|  | *National Center of Infectious and Parasitic Diseases (NCIPD)*  *26, Yanko Sakazov boul. 1504, Sofia, Bulgaria*  *Prof. Maria Nikolova, MD, Dsc*  *Head, Reference laboratory of Immunology*  *Head, Immunology and Allergy Department*  *E-mail:* [*mstoimenova@ncipd.org*](mailto:mstoimenova@ncipd.org)  *Reference laboratory for control and monitoring of antibiotics resistance* |
|  |  |

1. **IMPLEMENTED AND RUNNING PROJECTS**

|  |  |
| --- | --- |
| Projects related to virology, vaccines, infection diseases … | **National scientific program**: Innovative low-toxic biologically active precision medicine products (BioActMed), *2018, Partner. Funded by Ministry of Education and Science*  **Centre of Competence BG05M2OP001-1.002-0012-C0**1 Centre of Competences: Sustainable utilization of bio-resources and waste from healing and aromatic plants for innovative bioactive products 2018-2023; Strengthening research and innovation and enhancing education the field of innovative bioactive products. The establishment and operation of planned new facility for experimental cell and molecular biology will create new possibilities for employment of multi-parametric analytic approaches, new generation improvement of the workflow and enhance competitiveness of obtained experimental results. *2018, Partner, Operational Program Science and Education for Smart Growth 2014-2020 co-funded by ESF and ERDF*  **Research Infrastructure Cell Technologies in Biomedicine (INFRAACT**) of the National Roadmap for Research Infrastructure 2017-2023 funded by the Ministry of Education and Science (<http://out.easycounter.com/external/horizon2020.mon.bg>). Maim aim is to create technological platforms to serve pre-clinical cell and animal based scientific research by means of multi-omics-technologies; -cell biotechnologies; -in-vivo imaging; -cryobanking; -IT services and Bioinformatics  **Design of new supra-molecular nanoparticles**: spherical nucleic acids with polymeric and liposomal cores, 2017, *Partner, Funded by NSFB, Ministry of Education and Science*  Effects and mechanisms of impact of electrical discharges in gases and liquids on **model biological systems**, 2017, Partner, *Funded by NSF, Ministry of Education and Science* |
|  |  |